Risk of overactive bladder associated with cholinesterase inhibitors in dementia

BACKGROUND Although cholinesterase inhibitors (ChEIs) are the primary treatment for dementia, they are associated with overactive bladder (OAB), necessitating antimuscarinic use. Limited data exist regarding the risk of OAB across individual ChEIs in dementia. This study evaluated the risk of OAB as...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the American Geriatrics Society (JAGS) 2022-03, Vol.70 (3), p.820-830
Hauptverfasser:	Masurkar, Prajakta P., Chatterjee, Satabdi, Sherer, Jeffrey T., Chen, Hua, Johnson, Michael L., Aparasu, Rajender R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged antimuscarinics Cholinesterase inhibitors Cholinesterase Inhibitors - adverse effects Dementia Dementia - chemically induced Dementia - drug therapy Dementia disorders Diagnosis Donepezil Donepezil - therapeutic use Female Galantamine Galantamine - adverse effects Humans Male Medicare Morbidity Muscarinic Antagonists - adverse effects Older people overactive bladder Retrospective Studies Rivastigmine Rivastigmine - adverse effects United States - epidemiology Urinary Bladder, Overactive - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!